How effective is Arava for Systemic Lupus Erythematosus? (a real world drug study)
Summary:
Overall ratings: 2.8/5 Long term ratings: 3.8/5
This is a phase IV clinical study of how effective Arava (leflunomide) is for Systemic lupus erythematosus and for what kind of people. The study is created by eHealthMe from 10 Arava users and is updated continuously.
What is Arava?
Arava has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 76,040 Arava users. Check the latest studies of Arava.
What is Systemic lupus erythematosus?
Systemic lupus erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue) is found to be associated with 1,086 drugs and 1,645 conditions by eHealthMe. Check the latest studies of Systemic lupus erythematosus.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
10 people are studied for taking Arava in Systemic lupus erythematosus
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Arava effectiveness for Systemic lupus erythematosus (number of people):
Overall:
- not at all: 2
- somewhat: 3
- moderate: 2
- high: 1
- very high: 2
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 2
- high: 1
- very high: 1
Gender of people who take Arava for Systemic lupus erythematosus *:
- female: 100 %
- male: 0.0 %
Age of people who take Arava for Systemic lupus erythematosus *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 10 %
- 40-49: 10 %
- 50-59: 50 %
- 60+: 30 %
Who find Arava more effective for Systemic Lupus Erythematosus?
Gender of people who take Arava for Systemic lupus erythematosus *:
- female: 100 %
- male: 0.0 %
Age of people who take Arava for Systemic lupus erythematosus *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 66.67 %
- 60+: 33.33 %
* Approximation only. Some reports may have incomplete information.
Do you take Arava?
- You can start a phase IV clinical trial to monitor Arava safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Hania A, "Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report", Journal of Medical Cases, 2014 Aug .
- Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .
- Hania A, "Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report", Journal of Medical Cases, 2014 Aug .
- Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .
Related studies
Alternative drugs to, pros and cons of:
- Arava (76,040 reports)
Treatments, associated drugs and conditions:
- Systemic lupus erythematosus (76,948 reports)
How the study uses the data?
The study is based on leflunomide (the active ingredients of Arava) and Arava (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Renal Failure Aggravated and drugs of ingredients of primidone - now
- Could Symbicort cause Nerve Injury? - a second ago
- Bontril Pdm vs. Fish Oil, side effect and effectiveness comparison - a second ago
- Flecainide Acetate vs. Lanoxin, side effect and effectiveness comparison - 2 seconds ago
- Claritin and Wrist Fracture for Women aged 50-59 - 4 seconds ago
- Could Sertraline cause Infusion Site Reaction? - 6 seconds ago
- Gestational Diabetes and drugs of ingredients of diazepam - 7 seconds ago
- Drug interactions of Flomax and Acidophilus - 10 seconds ago
- Drug interactions of Allopurinol and Dilantin - 11 seconds ago
- Drug interactions of Adcirca and Ceftriaxone Sodium - 12 seconds ago